However, a long-term experiment with IM and other TKIs brought surprising results, indicating that a transient, but potent inhibition of BCR/ABL with IM, is sufficient to commit CML cells irreversibly to apoptosis [57]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.